Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal

Just three months after completing its $1.8 billion takeover of Agios’ oncology pipeline, Servier has reported positive results for lead drug Tibsovo that could expand the use of the drug in acute myeloid leukaemia.